On the other hand, nanoparticles targeting mutant TP53 can degrade mutant p53 and induce endoplasmic reticulum stress, thereby restoring cisplatin sensitivity in non-small cell lung cancer (NSCLC) (76). Here, TP53 is linked to non-small cell lung carcinoma.